Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$2.44 USD
-0.31 (-11.27%)
Updated Apr 17, 2024 03:59 PM ET
After-Market: $2.44 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADPT 2.44 -0.31(-11.27%)
Will ADPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?
Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Other News for ADPT
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Names Kyle Piskel New CFO
Adaptive Biotechnologies price target lowered by $1 at BTIG, here's why